Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Amplia receives grant to collaborate with CSIRO
Enrolment of Cohort 3 of ACCENT Trial in Pancreatic Cancer Complete
Quarterly Activities and Cash Flow Report - 31 March 2023
Archives
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
Categories
Company News
Media
Uncategorized
Videos
May 22nd, 2023
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Read More
February 6th, 2023
Channel 9 News | 3 February 2023
Read More
January 30th, 2023
PROACTIVE INTERVIEW | Dr Chris Burns
Read More
April 7th, 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
February 1st, 2022
VIDEO | PROACTIVE Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
Read More
November 30th, 2021
VIDEO | SMALL CAPS Amplia Therapeutics makes headway in anti-cancer clinical trial
Read More
November 18th, 2021
VIDEO | PROACTIVE Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
Read More
November 10th, 2021
VIDEO | AUSBIZ Amplia's $12M plan; what's next for the Aussie medtech
Read More
November 10th, 2021
VIDEO | Proactive Investors, $12.4m Capital Raise
Read More
September 29th, 2021
VIDEO | Proactive Lifesciences Webinar
Read More
September 20th, 2021
Proactive | Interview with Dr John Lambert
Read More
July 26th, 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
July 26th, 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
July 21st, 2021
Amplia Therapeutics returns successful phase one trial results
Read More
July 19th, 2021
Garvan's June Seminar: The Power of Personalised Medicine
Read More
June 30th, 2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Read More
June 28th, 2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
Read More
October 9th, 2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Read More
1
